Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Jenkin

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Canadian Journal of Surgery. Journal Canadien De Chirurgie|November 1, 2023
The impact of targeted fee increases on the pay disparity between female and male general surgeons in British ColumbiaHamish Hwang, Anise Barton, Daniel Jenkin, et al.
Vaccine|June 17, 2022
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessmentPedro M Folegatti, Daniel Jenkin, Susan Morris, et al.
The Lancet. Microbe|February 8, 2025
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trialDaniel Jenkin, Rebecca Makinson, Helen Sanders, et al.
Vaccine|December 15, 2024
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trialKerry Conlin, Daniel Jenkin, Philip de Whalley, et al.
Frontiers in Immunology|February 24, 2022
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From MalariaAndrés Noé, Mehreen S Datoo, Amy Flaxman, et al.
Vaccines|April 3, 2021
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex SubspeciesPedro M Folegatti, Amy Flaxman, Daniel Jenkin, et al.
The Lancet. Microbe|July 30, 2022
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trialDaniel Jenkin, Adam J Ritchie, Jeremy Aboagye, et al.
The Lancet. Infectious Diseases|April 15, 2023
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trialDaniel Jenkin, Daniel Wright, Pedro M Folegatti, et al.
The Lancet. Microbe|November 29, 2024
Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UKNicola Borthwick, Natalia Fernandez, Peter J Hayes, et al.
Ebiomedicine|October 13, 2022
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trialMeera Madhavan, Adam J Ritchie, Jeremy Aboagye, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Canadian Journal of Surgery. Journal Canadien De Chirurgie|November 1, 2023
The impact of targeted fee increases on the pay disparity between female and male general surgeons in British ColumbiaHamish Hwang, Anise Barton, Daniel Jenkin, et al.
Vaccine|June 17, 2022
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessmentPedro M Folegatti, Daniel Jenkin, Susan Morris, et al.
The Lancet. Microbe|February 8, 2025
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trialDaniel Jenkin, Rebecca Makinson, Helen Sanders, et al.
Vaccine|December 15, 2024
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trialKerry Conlin, Daniel Jenkin, Philip de Whalley, et al.
Frontiers in Immunology|February 24, 2022
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From MalariaAndrés Noé, Mehreen S Datoo, Amy Flaxman, et al.
Vaccines|April 3, 2021
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex SubspeciesPedro M Folegatti, Amy Flaxman, Daniel Jenkin, et al.
The Lancet. Microbe|July 30, 2022
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trialDaniel Jenkin, Adam J Ritchie, Jeremy Aboagye, et al.
The Lancet. Infectious Diseases|April 15, 2023
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trialDaniel Jenkin, Daniel Wright, Pedro M Folegatti, et al.
The Lancet. Microbe|November 29, 2024
Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UKNicola Borthwick, Natalia Fernandez, Peter J Hayes, et al.
Ebiomedicine|October 13, 2022
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trialMeera Madhavan, Adam J Ritchie, Jeremy Aboagye, et al.
Pageof 3